{
    "Clinical Trial ID": "NCT00068601",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Standard Chemotherapy",
        "  Patients receive cyclophosphamide-containing chemotherapy alone.",
        "  cyclophosphamide: Part of planned chemotherapy regimen",
        "INTERVENTION 2: ",
        "  Chemotherapy Plus Goserelin",
        "  Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.",
        "  cyclophosphamide: Part of planned chemotherapy regimen",
        "  goserelin acetate: Given subcutaneously"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive breast cancer",
        "  Stage I-IIIA",
        "  Operable disease",
        "  Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative",
        "  Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen containing alkylating agents (anthracyclines or non-anthracyclines), meeting 1 of the following criteria:",
        "  3-month/4-course anthracycline-based regimen",
        "  6- to 8-month/course anthracycline-based regimen",
        "  6- to 8-month/course non-anthracycline-based regimen",
        "  Hormone receptor status:",
        "  Estrogen receptor negative",
        "  Progesterone receptor negative",
        "  PATIENT CHARACTERISTICS:",
        "  Age",
        "  18 to 49",
        "  Sex",
        "  Female",
        "  Menopausal status",
        "  Premenopausal",
        "  Performance status",
        "  Zubrod 0-2",
        "  Life expectancy",
        "  Not specified",
        "  Hematopoietic",
        "  Not specified",
        "  Hepatic",
        "  Not specified",
        "  Renal",
        "  Not specified",
        "  Other",
        "  Not pregnant or nursing",
        "  Fertile patients must use effective barrier contraception",
        "  No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy",
        "  Not specified",
        "  Chemotherapy",
        "  See Disease Characteristics",
        "  No prior cytotoxic chemotherapy",
        "  Endocrine therapy",
        "  No other concurrent hormonal therapy",
        "  Radiotherapy",
        "  Concurrent radiotherapy to the breast, chest wall, or lymph nodes allowed",
        "  Surgery",
        "  See Disease Characteristics",
        "  Other",
        "  Concurrent participation in other therapeutic clinical trials, including SWOG-S0221, allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Rate of Premature Ovarian Failure at 2 Years",
        "  Ovarian failure at two years is defined as amenorrhea (absence of menstrual bleeding) for the preceding six months AND the presence of follicle-stimulating hormone (FSH) in the post-menopausal range.",
        "  Time frame: 2 years",
        "Results 1: ",
        "  Arm/Group Title: Standard Chemotherapy",
        "  Arm/Group Description: Patients receive cyclophosphamide-containing chemotherapy alone.",
        "  cyclophosphamide: Part of planned chemotherapy regimen",
        "  Overall Number of Participants Analyzed: 69",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  15  21.7%",
        "Results 2: ",
        "  Arm/Group Title: Chemotherapy Plus Goserelin",
        "  Arm/Group Description: Patients receive goserelin subcutaneously once every 4 weeks beginning 1 week before start of cyclophosphamide-containing chemotherapy. Treatment continues until completion of chemotherapy in the absence of disease progression or unacceptable toxicity.",
        "  cyclophosphamide: Part of planned chemotherapy regimen",
        "  goserelin acetate: Given subcutaneously",
        "  Overall Number of Participants Analyzed: 66",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  5   7.6%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/111 (0.00%)",
        "  Thrombosis/thrombus/embolism 0/111 (0.00%)",
        "Adverse Events 2:",
        "  Total: 1/103 (0.97%)",
        "  Thrombosis/thrombus/embolism 1/103 (0.97%)"
    ]
}